Literature DB >> 24487395

Increased soluble CD154 (CD40 ligand) levels in xenograft recipients correlate with the development of de novo anti-pig IgG antibodies.

Mohamed B Ezzelarab1, Burcin Ekser, Kumiko Isse, Hayato Iwase, Adrian E Morelli, David Ayares, David K C Cooper.   

Abstract

BACKGROUND: De novo anti-pig antibodies are associated with acute humoral xenograft rejection. We explored the relative efficacy of CD40/CD154-pathway blockade versus CD28/B7-pathway blockade in the prevention of de novo anti-pig IgG antibodies in xenograft recipients.
METHODS: After α1,3-galactosyltransferase gene-knockout pig artery patch xenotransplantation, recipient baboons received no immunosuppression (IS; n=3), or anti-CD154mAb-based (n=5) or CTLA4-Ig-based (n=5) IS. CD4 T-cell and CD20 B-cell numbers in blood were determined. Serum anti-pig IgG antibodies and serum soluble (s)CD154 levels were measured. In lymph nodes, germinal center formation was examined and numbers of proliferating cells were evaluated by Ki-67 staining.
RESULTS: After transplantation, with no IS, CD4 T-cell and CD20 B-cell numbers were increased, but were reduced by IS.In lymph nodes, with no IS, there was enhanced germinal center formation, which was significantly reduced by anti-CD154mAb-based (P<0.01) or CTLA4-Ig-based (P<0.01) IS. With no IS, there was strong expression of Ki-67-positive cells in lymph nodes, indicating extensive cellular proliferation. Ki-67-positive cells were significantly reduced by anti-CD154mAb-based (P<0.05) but not by CTLA4-Ig-based IS. High mean levels of sCD154 were detected with no IS (3324 pg/mL), in comparison to naive control baboons (214 pg/mL). With anti-CD154mAb-based IS, sCD154 was reduced to less than 1 pg/mL and with CTLA4-Ig-based IS to 65 pg/mL. There was significant positive correlation between sCD154 and anti-pig IgG levels (P<0.01).
CONCLUSIONS: In xenograft recipients, anti-CD154mAb may reduce class-switching of anti-pig antibodies by binding both T-cell surface CD154 and circulating sCD154, thus preventing subsequent stimulation of B cells and activation of lymphoid follicles in secondary lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24487395     DOI: 10.1097/TP.0000000000000042

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

2.  B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.

Authors:  Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase
Journal:  Transpl Immunol       Date:  2018-08-06       Impact factor: 1.708

3.  Therapeutic regulation of systemic inflammation in xenograft recipients.

Authors:  Hayato Iwase; Hong Liu; Tao Li; Zhongquiang Zhang; Bingsi Gao; Hidetaka Hara; Martin Wijkstrom; Cassandra Long; Ryan Saari; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2017-03-12       Impact factor: 3.907

4.  Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys.

Authors:  Rita Bottino; Michael F Knoll; Joshua Graeme-Wilson; Edwin C Klein; David Ayares; Massimo Trucco; David K C Cooper
Journal:  Xenotransplantation       Date:  2017-01-06       Impact factor: 3.907

Review 5.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Systemic inflammation in xenograft recipients precedes activation of coagulation.

Authors:  Mohamed B Ezzelarab; Burcin Ekser; Agnes Azimzadeh; Chih Che Lin; Yuming Zhao; Rachael Rodriguez; Gabriel J Echeverri; Hayato Iwase; Cassandra Long; Hidetaka Hara; David Ayares; Richard N Pierson; Angus W Thomson; David K Cooper
Journal:  Xenotransplantation       Date:  2014-09-11       Impact factor: 3.907

7.  In vitro testing of an anti-CD40 monoclonal antibody, clone 2C10, in primates and pigs.

Authors:  Whayoung Lee; Vikas Satyananda; Hayato Iwase; Takayuki Tanaka; Yuko Miyagawa; Cassandra Long; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Transpl Immunol       Date:  2015-10-12       Impact factor: 1.708

8.  T and B lymphocyte dynamics after genetically-modified pig-to-baboon kidney xenotransplantation with an anti-CD40mAb-based immunosuppressive regimen.

Authors:  Abhijit Jagdale; Huy Nguyen; Hayato Iwase; Jeremy B Foote; Takayuki Yamamoto; Mariyam Javed; David Ayares; Douglas J Anderson; Devin E Eckhoff; David K C Cooper; Hidetaka Hara
Journal:  Transpl Immunol       Date:  2022-01-31       Impact factor: 2.032

Review 9.  Evidence for the important role of inflammation in xenotransplantation.

Authors:  Juan Li; Hidetaka Hara; Yi Wang; Charles Esmon; David K C Cooper; Hayato Iwase
Journal:  J Inflamm (Lond)       Date:  2019-05-28       Impact factor: 4.981

10.  Data on B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.

Authors:  Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase
Journal:  Data Brief       Date:  2018-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.